Merck's HIV Gambit: New Drug, New Deal to Challenge Market Leaders

RAHWAY, NJ – June 29, 2026 – Pharmaceutical giant Merck has announced a pivotal agreement with the ADAP Crisis Task Force (ACTF) to ensure its newly approved HIV treatment, IDVYNSO™, is accessible through state-run assistance programs. While the move is a clear victory for public health, providing a modern treatment option to thousands of uninsured and underserved Americans, it also represents a shrewd strategic maneuver by Merck to carve out a larger share of the fiercely competitive multi-billion-dollar HIV market.

The deal, announced shortly after the drug's April 2026 FDA approval, aims to place IDVYNSO™ on the formularies of state AIDS Drug Assistance Programs (ADAPs), a critical safety net for over 250,000 people living with HIV in the United States. For Merck, this isn't just about corporate responsibility; it's about securing a crucial channel for market adoption and challenging the long-standing dominance of rivals like Gilead Sciences and ViiV Healthcare.

A Lifeline for the Underserved

ADAPs are the payers of last resort, a patchwork of state-managed programs funded by the federal Ryan White HIV/AIDS Program that provide life-saving medications to those who fall through the cracks of the American healthcare system. These programs are not entitlements and operate on finite budgets, making them perpetually vulnerable to fiscal pressures. The ability to provide a comprehensive formulary of the latest treatments depends heavily on their ability to negotiate steep discounts from manufacturers.

This is where the ADAP Crisis Task Force, a coalition of state health department officials, comes in. By negotiating as a bloc, the ACTF leverages its collective purchasing power to secure prices that individual states could never achieve alone. The agreement with Merck ensures that IDVYNSO™ will be available to these programs at a significant, though undisclosed, discount.

“ADAP programs play a critical role in supporting access to treatment for people living with HIV who are uninsured or underserved,” said Tim Horn, Director of Medication Access at the National Alliance of State and Territorial AIDS Directors (NASTAD), which provides support to the ACTF. “We appreciate Merck’s continued engagement and its willingness to work collaboratively to help address the critical access challenges facing state ADAP programs.”

For patients, this means access to a new, simplified treatment option without the financial barriers that often accompany innovative medicines. For Merck, it establishes an essential pathway to a significant patient population from the moment of launch, building physician familiarity and real-world evidence for its new product.

The Science of Simplification

IDVYNSO™ is a once-daily, single-tablet regimen combining two drugs: doravirine, an established non-nucleoside reverse transcriptase inhibitor (NNRTI), and islatravir, a next-generation nucleoside reverse transcriptase translocation inhibitor (NRTTI). This two-drug combination represents a broader industry trend toward simplifying HIV treatment, reducing the potential for long-term toxicities and side effects associated with older, more complex regimens.

Its FDA approval is specifically for adults who are already virologically suppressed on a stable antiretroviral regimen, positioning it as a “switch” option rather than a first-line treatment for newly diagnosed patients. This niche is significant, as many people living with HIV for years are looking for newer, more tolerable options to maintain their health long-term. The convenience of a single daily pill is a proven factor in improving patient adherence, which is paramount for maintaining viral suppression and preventing drug resistance.

“This agreement reflects our long-standing commitment to working with the ACTF, state ADAPs and the HIV community to strengthen access and help address persistent gaps in care,” said Conrod Kelly, head of Merck’s U.S. HIV business unit. The company also runs its own Merck Access Program to provide co-pay assistance and free medication for eligible patients, creating a multi-pronged approach to affordability.

However, IDVYNSO™ does not enter the market in a vacuum. It will compete directly with established two-drug regimens like ViiV's Dovato and must prove its value against Gilead’s market-leading single-tablet therapy, Biktarvy. Securing early and broad access through programs like ADAP is a critical first step in that battle.

The Strategic Blueprint: A Market Re-Entry

This aggressive access strategy is a cornerstone of Merck's larger plan to re-establish itself as a major force in HIV, a field it helped pioneer 40 years ago. The company's focus on its HIV portfolio has intensified as it faces the eventual patent expiration of its oncology cash cow, Keytruda. With executives eyeing a potential $5 billion opportunity in HIV, the success of IDVYNSO™ and its pipeline is essential for Merck's future growth.

The journey of islatravir, one of the components in IDVYNSO™, highlights the high-stakes nature of this research. Development of a once-monthly oral version for pre-exposure prophylaxis (PrEP) was halted in 2022 due to safety concerns. Its successful formulation at a lower dose within IDVYNSO™ marks a significant comeback for the promising compound and a testament to the company's persistence.

By partnering with the ACTF, Merck is not only facilitating patient access but also embedding its product within the public health infrastructure. Clinicians who treat ADAP-enrolled patients will gain experience with IDVYNSO™, potentially increasing their comfort level in prescribing it to their commercially insured patients as well. It’s a classic market-seeding strategy that aligns financial incentives with public health goals.

A Pipeline for the Future

Beyond IDVYNSO™, Merck’s ambitions in HIV are becoming clearer and more expansive. The company is betting heavily on the future of HIV care, moving beyond daily pills toward less frequent dosing for both treatment and prevention. Islatravir is being studied in combination with other agents for potential once-weekly oral treatments, a paradigm shift that could dramatically improve quality of life for people living with HIV.

Perhaps most significantly, Merck is advancing a new investigational drug, MK-8527, in Phase 3 trials as a potential once-monthly oral PrEP option. With the HIV prevention market currently dominated by daily pills and long-acting injectables, a safe and effective monthly pill could be a game-changer, capturing a substantial share of the market and fulfilling a major unmet need in global public health.

The agreement to secure broad access for IDVYNSO™ is more than a single product launch; it is the first major move in Merck's revitalized, long-term campaign to innovate and compete in the HIV space. By ensuring its latest science reaches some of the most vulnerable patients, Merck is making a powerful statement about its intentions for the bottom line.